Pfizer Company Profile

✉ Email this page to a colleague

PFIZER has one hundred and ninety-four approved drugs.

There are forty-eight US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are one thousand and twenty-two patent family members on PFIZER drugs in seventy countries and two hundred and fifty-nine supplementary protection certificates in nineteen countries.

International Patents:	1022
US Patents:	48
Tradenames:	159
Ingredients:	130
NDAs:	194
Drug Master File Entries:	3
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	URESE	benzthiazide	TABLET;ORAL	012128-003	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Pfizer	COLESTID	colestipol hydrochloride	GRANULE;ORAL	017563-004	Sep 22, 1995	AB	RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Pfizer	DEPO-TESTOSTERONE	testosterone cypionate	INJECTABLE;INJECTION	085635-002	Approved Prior to Jan 1, 1982	AO	RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379-004	May 19, 1997	5,741,523	⤷ Try a Trial
Pfizer	ZINECARD	dexrazoxane hydrochloride	INJECTABLE;INJECTION	020212-001	May 26, 1995	4,275,063	⤷ Try a Trial
Pfizer	TIKOSYN	dofetilide	CAPSULE;ORAL	020931-002	Oct 1, 1999	6,124,363	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	5 mg and 10 mg	➤ Subscribe	2005-06-21
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2011-06-17
➤ Subscribe	Oral Suspension	100 mg/5 mL	➤ Subscribe	2009-08-03
➤ Subscribe	Injection	2 mg/mL, 100 mL bag	➤ Subscribe	2009-12-29
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Delayed-release Tablets	50 mg/0.2 mg	➤ Subscribe	2009-06-29
➤ Subscribe	Extended-release Tablets	11 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	Capsules	75 mg, 100 mg and 125 mg	➤ Subscribe	2019-02-04
➤ Subscribe	Capsules	0.125 mg, 0.25 mg, and 0.5 mg	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	600 mg	➤ Subscribe	2005-12-21
➤ Subscribe	Injection	2 mg/mL, 300 mL bag	➤ Subscribe	2009-09-01
➤ Subscribe	Tablets	1 g	➤ Subscribe	2005-08-23
➤ Subscribe	Delayed-release Tablets	75 mg/0.2 mg	➤ Subscribe	2008-11-28
➤ Subscribe	Extended-release Tablets	4 mg and 8 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Injection	20 mg/mL, 2 mL and 5 mL vials	➤ Subscribe	2004-07-26

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822953	2019C/539	Belgium	⤷ Try a Trial	DETAILS ASSIGNMENT: CHANGE OF OWNER(S), OTHER
1746999	19C1052	France	⤷ Try a Trial	PRODUCT NAME: DACOMITINIB, Y COMPRIS UN DE SES HYDRATES, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/19/1354 20190404
1746976	1790033-3	Sweden	⤷ Try a Trial	PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT.; REG. NO/DATE: EU/1/16/1130 20161008
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.